NCCN Update

August 2020, Vol 1, No 1 — September 10, 2020
The National Comprehensive Cancer Network (NCCN) added the targeted agent ivosidenib (Tibsovo) to its recent 2020 hepatobiliary cancers guidelines update, which was published on June 1, 2020.1 Recommendations within the NCCN’s hepatobiliary cancers guidelines are derived from critical evaluation of evidence, integrated with the clinical expertise and consensus of a multidisciplinary panel of cancer specialists, clinical experts, and researchers.
Read More

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: